Immunological monitoring in a controlled trial of immunotherapy in stage IIB malignant melanoma.

Fifteen patients undergoing surgery for Stage IIb malignant melanoma were randomly allocated either to a group who received a vaccine of BCG mixed with irradiated autologous melanoma cells, or a control group who received no further treatment. All patients were monitored sequentially for immunologic...

Descripción completa

Detalles Bibliográficos
Autores principales: Embleton, M. J., Ransom, J. H., McIllmurray, M. B., Reeves, W. G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1978
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009553/
https://www.ncbi.nlm.nih.gov/pubmed/565645
_version_ 1782136137857368064
author Embleton, M. J.
Ransom, J. H.
McIllmurray, M. B.
Reeves, W. G.
author_facet Embleton, M. J.
Ransom, J. H.
McIllmurray, M. B.
Reeves, W. G.
author_sort Embleton, M. J.
collection PubMed
description Fifteen patients undergoing surgery for Stage IIb malignant melanoma were randomly allocated either to a group who received a vaccine of BCG mixed with irradiated autologous melanoma cells, or a control group who received no further treatment. All patients were monitored sequentially for immunological competence and tumour-directed immunity, using a wide range of techniques, and the results were compared retrospectively with their clinical course. Three months after surgery, there was a trend towards inhibition of PHA-induced lymphocyte transformation by autologous serum in patients who developed recurrent tumour within 12 months after treatment. Serum from patients who remained tumour-free for 12 months did not inhibit stimulation of autologous lymphocytes by PHA. Apart from this test, no other immunological parameters correlated either with clinical course or with the type of treatment received.
format Text
id pubmed-2009553
institution National Center for Biotechnology Information
language English
publishDate 1978
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20095532009-09-10 Immunological monitoring in a controlled trial of immunotherapy in stage IIB malignant melanoma. Embleton, M. J. Ransom, J. H. McIllmurray, M. B. Reeves, W. G. Br J Cancer Research Article Fifteen patients undergoing surgery for Stage IIb malignant melanoma were randomly allocated either to a group who received a vaccine of BCG mixed with irradiated autologous melanoma cells, or a control group who received no further treatment. All patients were monitored sequentially for immunological competence and tumour-directed immunity, using a wide range of techniques, and the results were compared retrospectively with their clinical course. Three months after surgery, there was a trend towards inhibition of PHA-induced lymphocyte transformation by autologous serum in patients who developed recurrent tumour within 12 months after treatment. Serum from patients who remained tumour-free for 12 months did not inhibit stimulation of autologous lymphocytes by PHA. Apart from this test, no other immunological parameters correlated either with clinical course or with the type of treatment received. Nature Publishing Group 1978-04 /pmc/articles/PMC2009553/ /pubmed/565645 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Embleton, M. J.
Ransom, J. H.
McIllmurray, M. B.
Reeves, W. G.
Immunological monitoring in a controlled trial of immunotherapy in stage IIB malignant melanoma.
title Immunological monitoring in a controlled trial of immunotherapy in stage IIB malignant melanoma.
title_full Immunological monitoring in a controlled trial of immunotherapy in stage IIB malignant melanoma.
title_fullStr Immunological monitoring in a controlled trial of immunotherapy in stage IIB malignant melanoma.
title_full_unstemmed Immunological monitoring in a controlled trial of immunotherapy in stage IIB malignant melanoma.
title_short Immunological monitoring in a controlled trial of immunotherapy in stage IIB malignant melanoma.
title_sort immunological monitoring in a controlled trial of immunotherapy in stage iib malignant melanoma.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009553/
https://www.ncbi.nlm.nih.gov/pubmed/565645
work_keys_str_mv AT embletonmj immunologicalmonitoringinacontrolledtrialofimmunotherapyinstageiibmalignantmelanoma
AT ransomjh immunologicalmonitoringinacontrolledtrialofimmunotherapyinstageiibmalignantmelanoma
AT mcillmurraymb immunologicalmonitoringinacontrolledtrialofimmunotherapyinstageiibmalignantmelanoma
AT reeveswg immunologicalmonitoringinacontrolledtrialofimmunotherapyinstageiibmalignantmelanoma

Ejemplares similares